Following the success of Bio-Asia 2025, WCC is moving forward to further showcase our innovations in the healthcare field. We are driving change not only in nutrition but also in pharmaceutical products.
In the nutrition segment, we will soon launch two of our latest products—one designed to enhance energy and endurance, and another to help soothe muscle soreness and joint discomfort caused by intense outdoor activities.
On the pharmaceutical side, we plan to initiate a Phase 1 clinical trial in early 2026 for our pain-relief microarray patches (MAPs) incorporating diclofenac sodium as the main active ingredient.
As stated by our Chairman in a PR Newswire feature: “Our WINMAP™ platform sets a new standard for producing microneedles — with an unprecedented combination of high-precision molds, accurate drug loading, and efficient, scalable mass production.”
Key features of the WINMAP™ platform include:
- Needle-free, pain-free delivery: Eliminates the need for syringes, reducing infection risk and minimizing patient discomfort.
- Scalable production: Automated manufacturing lines capable of producing over 10 million MAPs annually with high yield and consistency.
- Precision Loading and Coating (PLC) process: Offers customizable molding, accurate dosing, smart drying, and proprietary coating technologies.
- Advanced formulation databases: The Microneedles Material Database (MMDB) and Microneedles Formulation Database (MFDB) enable rapid development of MAPs with tailored release profiles, ranging from rapid onset to controlled delivery.
Building on our proven innovation in microneedle-based platforms, WCC is currently conducting a fundraising round with a minimum target of US $7 million to scale up commercial production, with an IPO planned for 2027. As we sharpen our focus on pharmaceutical and vaccine applications, we also plan to launch several new products in Q1 2026 and list on Taiwan’s Emerging Stock Board.
For further reading, please refer to our PR Newswire coverage.